PMLive19h
FDA approves Celltrion’s denosumab biosimilars Stoboclo and Osenvelt
The US Food and Drug Administration (FDA) has approved Celltrion’s biosimilars referencing Amgen’s bone disease therapy ...
Healio6d
Two new denosumab biosimilars earn FDA approval
The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...
Healio6d
First four Stelara biosimilars launch in US; ‘white labeling’ threatens market ‘vibrancy’
Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...
With patent losses on the horizon, Amgen refocuses its business strategy
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its ...
The Pharma Letter6d
FDA nod for two Celltrion denosumab biosimilars
South Korea-based Celltrion today announced that the US Food and Drug Administration (FDA) has approved Stoboclo and Osenvelt ...
Behind the Scenes of Amgen's Latest Options Trends
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale ...
Fierce Pharma13d
J&J takes Samsung Bioepis to court over claims Korean company breached Stelara biosim settlement
Johnson & Johnson on Monday filed a lawsuit against Samsung Bioepis in a New Jersey federal court, accusing the Korean ...
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Nasdaq6d
Celltrion's STOBOCLO And OSENVELT Biosimilars Get FDA Approval Referencing Amgen's PROLIA And XGEVA
biosimilars for all indications of reference products PROLIA (denosumab) and XGEVA (denosumab) respectively, from Amgen Inc. (AMGN). In accordance with a settlement agreement with Amgen ...
Drug Store News5d
Celltrion receives FDA nod for Prolia, Xgeva biosimilars
Celltrion has received permission from the Food and Drug Administration for Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt ...
Amgen (AMGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
JD Supra3d
FDA Approves Celltrion’s Denosumab Biosimilars
On March 3, 2025, the FDA approved Celltrion’s denosumab biosimilars, STOBOCLO® (denosumab-bmwo; 60 mg/mL injection) and OSENVELT® (denosumab-bmwo; ...